MannKind Corporation — Form 10-Q Summary
Business context and reporting period
Development-stage biopharmaceutical company focused on diabetes and cancer therapies. The lead candidate, AFREZZA, is an ultra-rapid-acting inhaled insulin product using the Technosphere platform and remains unapproved. This report covers the three months ended March 31, 2012; the filing was signed May 10, 2012.
Financial performance and condition
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Revenue | $0 | $50,000 | Down $50,000 |
| Research and development expense | $24.2 million | $26.3 million | Down 8% |
| General and administrative expense | $9.8 million | $11.8 million | Down 17% |
| Operating loss | $33.9 million | $38.0 million | Improved $4.1 million |
| Net loss | $38.2 million | $41.5 million | Improved $3.4 million |
| Net loss per share | $0.27 | $0.34 | Improved $0.07 |
| Cash used in operations | $32.5 million | $30.7 million | Increased $1.8 million |
With no product revenue, gross and operating margins are not meaningful. The company reported a comprehensive loss of $38.1 million. Other income was $1.4 million, including a forward purchase contract benefit, partly offset by a $117,000 investment impairment and a $284,000 warrant-liability fair-value loss. Interest expense rose to $5.6 million from $4.9 million, primarily because of additional related-party borrowings.
At March 31, 2012, cash and cash equivalents were $56.4 million, marketable securities were $350,000, and total current assets were $59.7 million. Total liabilities were $528.8 million, including $210.9 million of senior convertible notes and $283.5 million owed under the related-party loan arrangement. Stockholders’ deficit was $277.4 million.
Material changes versus the prior comparable period
- February 2012 public offering of 35.9 million units generated approximately $80.6 million of net proceeds and included warrants to purchase 21.6 million shares.
- Common shares outstanding increased to 167.8 million at March 31, 2012 from 131.5 million at December 31, 2011, before considering additional potential dilution.
- Clinical expense increased 69% to $10.9 million as AFREZZA studies 171 and 175 began screening subjects.
- Manufacturing expense declined 30% and research expense declined 54%; management attributed overall R&D and administrative reductions mainly to the February 2011 workforce reduction.
- Cash used in operations increased despite the lower net loss, principally because of higher clinical-trial spending.
Outlook, liquidity, risks, and unusual items
Management expected the two FDA-requested AFREZZA studies to be completed in early 2013 and anticipated submitting results as an NDA amendment in the second half of 2013. The filing cautions that trial results may be insufficient, the FDA may request additional studies, and approval is not assured.
Management expected existing capital resources and $38.8 million of remaining related-party borrowing capacity to fund planned operations into the fourth quarter of 2012. The company explicitly stated that substantial doubt exists about its ability to continue as a going concern and that additional equity, debt, collaboration, licensing, asset sales, or related-party financing will be needed.
The related-party loan had a March 31, 2012 maturity extension to March 31, 2013, with borrowing availability through June 30, 2012. The filing also disclosed a May 9, 2012 amendment extending maturity to July 1, 2013. The lender may require repayment of up to $200 million of eligible advances, subject to stated conditions.
Material risks include AFREZZA’s prior FDA Complete Response letter, clinical and regulatory uncertainty, lack of commercial products, continued negative cash flow, substantial debt and dilution risk, dependence on the related-party lender, manufacturing and supply risks, intellectual-property claims, and securities class-action and derivative litigation. The company stated that expected litigation losses were not expected to materially affect the financial statements, although settlement negotiations were ongoing.
Important facts for investors to verify
- Whether AFREZZA studies 171 and 175 met enrollment, safety, efficacy, and timing expectations and whether the FDA accepted the resulting NDA amendment.
- Actual cash burn and financing availability relative to the stated fourth-quarter 2012 liquidity outlook.
- Status, terms, and repayment requirements of the related-party loan and the July 1, 2013 maturity extension.
- Stockholder approval and settlement of The Mann Group’s proposed $77.2 million restricted-share purchase, including the planned increase in authorized shares.
- Potential dilution from convertible notes, 21.6 million warrants, equity awards, share-lending arrangements, and other reserved shares.
- Developments in the securities class actions and derivative lawsuits, including any settlement or material loss estimate.